Please read our student and staff community guidance on COVID-19
Skip to main content Skip to navigation

De-ESCALaTE HPV

Determination of Epidermal growth factor receptor inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus positive oropharyngeal squamous cell carcinoma

Portfolio Study ID: 11723

_____________________________________________________________________________________________________________________

De-ESCALaTE is a pragmatic, randomised, international, multi-centre, open label, Phase III clinical trial determining the optimum treatment for patients with HPV+ OPSCC.

Sponsored by the University of Warwick. Funded by Cancer Research UK.

 

GENERAL ENQUIRES:

Please email the De-ESCALaTE Team at deescalate@warwick.ac.uk

-------------------------------------

The trial is closed to new sites and now closed to recruitment.

The main results of the study were published in 2018: Main Trial Results Summary

 

Trial Schema 2015

 logos.jpg

Logo

Trial Administrator

Matthew Dalby

Tel: +44 (0)2476572721

Email: m.l.dalby@warwick.ac.uk

 

Data Entry Clerk

Liz Weaver

Tel: +44 (0)2476573142

Email:

e.weaver@warwick.ac.uk